721-01-7

Usage

Uses

Used in Pharmaceutical Industry:
2,4(1H,3H)-Pyrimidinedione, 1-(phenylmethoxy)is used as a building block in the synthesis of various heterocyclic compounds, which are essential in the development of new pharmaceutical drugs. Its potential as a DNA intercalator and its anti-tumor and anti-inflammatory properties make it a promising candidate for the treatment of various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 2,4(1H,3H)-Pyrimidinedione, 1-(phenylmethoxy)is used as a starting material for the synthesis of various agrochemical products, such as pesticides and herbicides. Its versatility in organic synthesis allows for the creation of new compounds with improved efficacy and reduced environmental impact.
Used in Materials Science:
2,4(1H,3H)-Pyrimidinedione, 1-(phenylmethoxy)is used as a component in the development of new materials with unique properties. Its potential applications in materials science include the creation of advanced polymers, composites, and other materials with enhanced performance characteristics.

Upstream product

• 7424-91-1 methyl 3,3-dimethoxypropionate 
• 2048-50-2 benzyloxyurea 
• 262293-82-3 3,3-dimethoxypropionic acid ethyl ester 
• 622-33-3 N-benzyloxyamine 
• 10601-80-6 ethyl 3,3-diethoxypropanoate 
• 36056-90-3 ethyl 3,3-diethoxy-2-methylpropionate 

Downstream Products

• 18009-45-5 3-Benzyloxyimino-2,2-dichlor-propionsaeureamid 
• 6584-65-2 N-1-Hydroxyuracyl 
• 2048-52-4 1-benzyloxycytosine 
• 1194473-24-9 1-hydroxy-3-benzylpyrimidin-2,4-dione 
• 189497-34-5 tris(2-(6-{1-[1-(benzyloxy)-2-oxo-1,2-dihydropyrimidin-4-yl]amino}octanamido)ethyl)amine 
• 189497-32-3 tris(2-(6-{1-[1-(benzyloxy)-2-oxo-1,2-dihydropyrimidin-4-yl]amino}heptanamido)ethyl)amine 
• 189497-30-1 tris(2-(6-{1-[1-(benzyloxy)-2-oxo-1,2-dihydropyrimidin-4-yl]amino}hexanamido)ethyl)amine 
• 189497-28-7 4-[(7-carboxyheptyl)amino]-1-(benzyloxy)-2(1H)-pyrimidinone O-succinimide ester 
• 189497-26-5 4-[(6-carboxyhexyl)amino]-1-(benzyloxy)-2(1H)-pyrimidinone O-succinimide ester 
• 189497-25-4 4-[5-(carboxy)pentylamino]-1-(benzyloxy)pyrimidin-2(1H)-one-O-succinimide 
• 189497-20-9 4-{[7-(methoxycarbonyl)heptyl]amino}-1-(benzyloxy)-2(1H)-pyrimidinone 
• 189497-19-6 4-{[6-(methoxycarbonyl)hexyl]amino}-1-(benzyloxy)-2(1H)-pyrimidinone 
• 189497-16-3 4-[5-(methyloxycarbonyl)-pentylamino]-1-(benzyloxy)-2(1H)-pyrimidinone 
• 189497-24-3 4-[(7-carboxyheptyl)amino]-1-(benzyloxy)-2(1H)-pyrimidinone 

Relevant academic research and scientific papers

NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY

The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).

Synthesis of N-1-oxypyrimidine 1,3-dioxolane and 1,3-oxathiolane nucleosides

Two series of 1,3-dioxolanes and 1,3-oxathiolane nucleosides containing N-1-oxypyrimidine were synthesized as potential antiviral agents.

Novel Iron Sequestering Agents: Synthesis and Iron-Chelating Properties of Hexadentate Ligands Composed of 1-Hydroxy-2(1H)-pyrimidinone, ω-Amino Carboxylic Acid, and Tris(2-aminoethyl)amine

Novel heterocyclic hexadentate ligands (3HOPYn: n = 5-7), in which three units of 1-hydroxy-2(1H)-pyrimidinone are linked to tris(2-aminoethyl)amine through an amide bond by an alkyl chain, were synthesized, and their iron-chelating properties were investigated. The stability of their iron complexes (25 to 27 in log K) was significantly larger than that of pyrazinone-containing ligands by virtue of higher pKa values. On kinetic evaluation of iron removal from human transferrin, 3HOPY5 showed remarkable efficiency over five times as much as commercially available desferrioxamine B. The conformational analysis of the corresponding Ga(III) complex of Fe(opy5) by 1H NMR and by MM and MD calculations are also discussed.